Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report
Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report
复制标题
DOI：
10.3892/ol.2019.10027
复制
发表时间：
2019-04-01
期刊：
影响因子：
2.9
通讯作者：
Kume, Haruki
中科院分区：
文献类型：
--
作者：
Azuma, Takeshi;Sugihara, Tohru;Kume, Haruki
使用酪氨酸激酶抑制剂（TKI）和哺乳动物靶点雷帕霉素抑制剂的序贯治疗是转移性肾细胞癌的主要治疗方法。最近，抗程序性死亡-1（PD-1）抗体，一种免疫检查点抑制剂，被批准用于治疗转移性肾细胞癌。在本报告中，描述了两例 TKI 难治性转移性肾细胞癌病例，在纳武单抗免疫治疗后恢复了对 TKI 的敏感性。在一个病例中，纳武单抗治疗后第三次阿西替尼挑战导致肿瘤缩小，尽管在纳武单抗治疗前立即使用阿西替尼第二次挑战没有效果。在另一个病例中，纳武单抗治疗后第二次帕唑帕尼挑战略微减少了肺转移，而纳武单抗治疗前帕唑帕尼对肺转移是难治性的。这些病例表明纳武单抗可以影响后续 TKI 治疗的反应。
Sequential therapy using tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin inhibitors is the mainstay of treatment for metastatic renal cell carcinoma. Recently, anti-programmed death-1 (PD-1) antibody, a type of immune checkpoint inhibitor, was approved for use against metastatic renal cell carcinoma. In the present report, two cases of TKI-refractory metastatic renal cell carcinoma which regained sensitivity to TKI after immunotherapy with nivolumab were described. In one case, a third challenge with axitinib after nivolumab treatment resulted in tumor shrinkage, although the second challenge with axitinib immediately before nivolumab treatment had no effect. In another case, a second challenge with pazopanib after nivolumab slightly reduced lung metastasis, which was refractory to pazopanib before nivolumab treatment. These cases suggest that nivolumab can influence the response to subsequent TKI treatment.